HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hard Truths About Mistruths: US FDA’s Califf Switching Gears On Misinformation Fight

Executive Summary

Fighting misinformation likely will not be successful, the FDA commissioner concedes, but stakeholders should join the campaign to increase the dissemination of truthful information.

You may also be interested in...



Combatting Misinformation: FDA’s Califf On Use Of Facts, Opinion And Emotion

As discussion continues on the role of artificial intelligence in tackling misinformation and who gets to decide what information AI synthesizes, Califf and CBER’s Peter Marks call on clinical and biomedical community to dilute misinformation about vaccines with large amounts of scientific evidence.

Pharma Could Lose Some Commercial Info Protections As Part of FDA’s Misinformation Campaign

Commissioner says agency’s speech restrictions to protect confidential commercial information ‘have gone too far,’ and may need to be modified to tackle spread of misinformation. Experts also said US FDA needs to do a better job conveying the uncertainty inherent in its work.

Prebunk: FDA Needs To Get Ahead Of Misinformation, But It Likely Can’t Drive The Effort

New report offers a five-point plan for FDA to improve the public’s understanding of its role including pushing the agency to be more proactive in listening for, spotting, and addressing misconceptions before they escalate. But experts caution that this must be done carefully, or it could fuel more distrust.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel